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Letter to the Editors:
Inaugural meeting of the Consortium for Blood Group Genes (CBGG): a summary report
Over half a century ago the serologic analysis of blood group antigens established its roots in the clinical
transfusion laboratory. The evaluation and laboratory investigation of alloimmunization,which occurred as a result
of pregnancy or after RBC and platelet transfusion, was quickly developing into the field of immunohematology.
Moreover, blood group phenotyping became a powerful tool to provide antigen-matched RBCs, to evaluate the
differences in blood group antigen expression between individuals, and to infer the inheritance of the genes that
express these antigens. Of course, a natural progression of the latter included the analysis of the genes and alleles
that are responsible for the expression of the antigens. The ease with which molecular biological techniques
became user friendly and adaptable to the clinical laboratories made this progression possible.
In 1993, Bennett and associates published a landmark paper on the clinical application of molecular blood
group genotyping, although their initial application was not true “genotyping”as it merely confirmed the presence
of the RHD gene. The unique application used DNA derived from cells in amniotic fluid to “infer” the blood group
of fetuses at risk for HDN due to anti-D,1 thus alleviating the risk associated with cordocentesis to establish the D
antigen of a fetus. Today, 50 percent of pregnancies at risk for the common antibodies implicated in HDN, when
the father is heterozygous for the corresponding allele, are deemed to be antigen-negative and not at risk for the
disease. Clinical management varies, but essentially the mother can return to her primary care physician and
noninvasive procedures can be used to monitor for fetal anemia. A decade after the publication of Bennett et al.,
other molecular applications are being published with unprecedented speed. The DNA analysis of blood group
genes has expanded to include the following uses:
1) Genotype multi-transfused recipients, patients with severe thrombocytopenia, and those whose RBCs or
platelets are sensitized with antibodies
2) Resolve ABO and Rh D discrepancies
3) Identify some of the Rh D variants that are at risk for anti-D alloimmunization
4) Determine RHD zygosity
5) Confirm the true genotype when an antigen is weakly expressed, e.g., Del
6) Identify whether the Fyb– transfusion recipient can safely receive Fyb+ RBCs
7) Mass screen for antigen-negative and rare RBCs
8) Genotype donors for antibody identification panels
During the 1950s and 1960s people with a common interest in blood group serology formed focus groups to
disseminate and exchange information, mentor young scientists, and advance our understanding of the field of
immunohematology. So too has the study of the genes that express blood group antigens become an entity itself.
The inaugural meeting of the Consortium for Blood Group Genes (CBGG) was held during the AABB annual
meeting on October 23, 2004, in Baltimore, Maryland. The meeting was attended by 24 delegates from North and
South America, with contributions from other colleagues who could not attend. The group was formed out of
these:
• A common interest in the genes that express RBC, platelet, and neutrophil antigens
• A desire to promote the use of molecular technology in the clinical lab
• The need for DNA reference samples
• The establishment of a proficiency program and standards of practice.
A summary of the meeting is provided in this report. All interested readers are encouraged to get involved and
embrace the opportunity to discuss and promote scientific inquiry in blood group genes. It is anticipated that
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clinical and scientific advancements in the study of the genes that express blood group antigens will continue as
a result of global interaction. The next meeting will be held prior to the October 2005 AABB Annual Meeting in
Seattle.
Consortium for Blood Group Genes
1) Language
Group meetings and interactions will be conducted in English.
2) Membership
Membership is open to those with an interest in single nucleotide polymorphisms and other genetic
variations that are of interest to transfusion medicine, i.e., RBC, platelet, and neutrophil antigens.
Interaction with other existing networking formats is encouraged, e.g.,AABB Special Interest Groups.
3) Name
The name of the organization is the Consortium for Blood Group Genes (CBGG).
4) Web Site
A Web site will be established in the near future.
5) Working Parties
Working parties of volunteers were established to investigate, collate, and disseminate recommendations
to the entire group on the areas listed below.
a. Proficiency Program
One role of the CBGG is to contribute to and participate in proficiency testing much like
immunohematology reference laboratories (IRLs), with two samples exchanged per year. One goal of
proficiency testing is to have a forum for DNA testing verification and results analysis. The working
party will recommend a practical, low-cost proficiency program.
b. Forms and Disclaimers 
Blood group genetic clinical reports were discussed and those members who provide clinical reports
were asked to share copies of their reports to give a feel for the types of disclaimers they use. The
group could help unify reports and set the standards for DNA blood group testing forms and reports
and recommended disclaimers. The clinical forms and reports section will be addressed by a working
party.
c. Reference DNA samples 
There is a need to establish a source of samples for control and for validation purposes. It is anticipated
that standard DNA reference samples will be made available as well as a listing of important DNA single
nucleotide polymorphisms, amplification primers, and standard protocols.
d. Standards
The CBGG has the potential to develop standards for its members and act as a voice to regulatory
bodies as the testing becomes more commonplace. An FDA representative has been contacted since
the inaugural meeting. The group is encouraged to see an open partnership developing that will
communicate needs and issues and ensure appropriate compliance.
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e. Funding
Sources of funding were discussed. Possibilities included a nominal membership fee (e.g., $100), a fee
for shipping DNA from the repository, and a fee for participating in the proficiency program. Other
potential sources of funding were identified.
f. Structure and Bylaws 
The structure, bylaws, and mechanism for nominating officers to represent the consortium are in the
initial stages.
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